



HIV Therapy

2009




FRINNOV

www.frinnov.fr

"IP Overview - HIV Therapy" - The HIV Paradox

Patent global landscape as a new tool to decipher market trends

Discovered in 1983, the HIV virus has been the subject of intensive research and development within the academic and industrial sectors. With the perspective of a global market of 10 billion US\$, applicants filed more than 6800 patents and patent applications.



Protease and Reverse Transcriptase Inhibitors were the first therapies to be investigated and still are the major therapies on the market. Entry and Integrase inhibitors were then investigated since 1995 and are now the major therapeutics under clinical development.

Despite the huge increase in HIV market and the needs for new therapies, multiple signals are showing that HIV research and development is running short of new thematic and is practically collapsing since 2005 with a 40% drop in the number of patent applications. This paradox hides multiple scenarios with former leaders becoming followers and new companies emerging on specific or yet unexplored segments. In the same times, new collaborations are forming changing drastically acquired positions between established players.

After 25 years of successes and drawbacks in the treatment of HIV, this IP Overview provides you with a comprehensive panorama of the intellectual property landscape and helps you

- Position your company's R&D and IP Portfolio
- Identify key inventors and key players involved in specific thematic and/or therapeutic target
- Understand the collaboration networks and theirs dynamics
- Uncover trends and emerging segments

Summary

METHODOLOGY	8
INTRODUCTION	9
1 BRIEF OUTLINE OF THE MARKET	12
2 A BRIEF OUTLINE OF THE PIPELINE	14
3 PROTECTION STRATEGIES	15
3.1 Evolution of patent filings	15
3.2 Priority patent applications	16
3.3 Extensions	18
3.4 Analysis of industrial patents over time	19
3.5 Study of the granting of US patents	20
3.6 Study of the granting of European patents	22
3.7 Evolution of the number of applicants	23
4 TOPOLOGY OF PATENTS IN THE SECTOR	25
4.1 Breakdown of patents into therapeutic targets	25
4.2 Breakdown of patents by application	27
4.3 Cross-analysis of the categories "applications" and "therapeutic targets"	30
4.4 Breakdown of patents by class of compounds	31
4.5 Cross-analysis of the categories "class of compound" and "therapeutic target"	33
4.6 Cross-analysis of the categories "class of compound" and "application"	34
4.7 Breakdown of the main IPC codes of patents	35
5 APPLICANTS	37
5.1 Analysis for the entire period (1983-2006)	37
5.1.1 Main applicants (1983-2006)	37
5.1.2 Collaborations (1983-2006)	38

5.1.3 Topics protected (1983-2006)	41
5.2 Analysis for the pioneer period (1983-1992)	45
5.2.1 Pioneer applicants (1983-1992)	45
5.2.2 Collaborations from 1983-1992	46
5.2.3 Topics protected (1983-1992)	49
5.3 Analysis for the intermediary period (1993-2000)	53
5.3.1 Main applicants (1993-2000)	53
5.3.2 Collaborations (1993-2000)	54
5.3.3 Topics protected (1993-2000)	57
5.4 Analysis for the most recent period (2001 - 2006)	61
5.4.1 Major applicants (2001-2006)	61
5.4.2 Collaborations (2001-2006)	63
5.4.3 Protected topics (2001-2006)	65
6 INVENTORS IN THE FIELD	69
6.1 Inventors for the entire period (1983-2006)	69
6.1.1 The main inventors	69
6.1.2 The experts	71
6.1.3 Mobility of inventors	71
6.1.4 Research teams for the entire period (1983-2006)	73
6.1.5 Topics	74
6.1.6 Description of the main inventors	77
6.2 Pioneer inventors (1983-1992)	79
6.3 Main inventors from 1993 to 2000	85
6.4 Main inventors from 2001 to 2006	92
6.5 Emerging inventors	99
7 CONCLUSION	100
7.1 No novel therapies in sight	100
7.2 Repositioning of the major industrial players	101
7.3 Market players to redefine their strategies	103

Figures and tables

FIGURE 1:	NUMBER OF PEOPLE LIVING WITH HIV (2007) ¹	9
FIGURE 2:	HIV REPLICATION CYCLE	10
TABLE 1:	THERAPEUTIC TARGETS EXPLORED IN THE MANY STEPS OF THE VIRAL REPLICATION CYCLE	10
FIGURE 3:	HIV THERAPY MARKET EVOLUTION PROSPECTS AND THE MAIN PLAYERS	12
FIGURE 4:	MOLECULES UNDER DEVELOPMENT BY CLASS OF ANTIVIRAL (ALREADY MARKETED)	14
FIGURE 5:	MOLECULES UNDER DEVELOPMENT BY CLASS OF ANTIVIRAL (NOT YET MARKETED)	14
FIGURE 6:	EVOLUTION IN PATENT FILINGS	15
FIGURE 7:	GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS	16
FIGURE 8:	GEOGRAPHIC DISTRIBUTION OF PRIORITY FILINGS/CLOSE-UP: EUROPE	17
TABLE 2:	EVOLUTION OF PRIORITY FILINGS	17
FIGURE 9:	GEOGRAPHIC DISTRIBUTION OF EXTENSIONS	18
TABLE 3:	EVOLUTION OF EXTENSIONS	18
FIGURE 10:	EVOLUTION OF THE BREAKDOWN OF INDUSTRIAL PATENTS	19
FIGURE 11:	EVOLUTION OF AVERAGE GRANT TIME FOR US PATENTS	20
FIGURE 12:	EVOLUTION OF THE GRANTING OF US PATENTS	21
FIGURE 13:	EVOLUTION OF THE AVERAGE GRANT TIME OF EP PATENTS	22
FIGURE 14:	EVOLUTION OF THE GRANTING OF EP PATENTS	23
FIGURE 15:	EVOLUTION OF THE NUMBER OF APPLICANTS	24
FIGURE 16:	BREAKDOWN OF THE PORTFOLIO BY THERAPEUTIC TARGET	26
TABLE 4:	EVOLUTION OF THE BREAKDOWN BY THERAPEUTIC TARGET	26
FIGURE 17:	BREAKDOWN OF THE PORTFOLIO BY APPLICATION	28
TABLE 5:	EVOLUTION OF THE BREAKDOWN BY APPLICATION	29
FIGURE 18:	CROSS-ANALYSIS OF THE CATEGORIES APPLICATIONS AND THERAPEUTIC TARGETS	30
FIGURE 19:	BREAKDOWN OF PATENTS BY CLASS OF COMPOUND	32
TABLE 6:	EVOLUTION IN THE BREAKDOWN BY CLASS OF COMPOUND	32
FIGURE 20:	CROSS-ANALYSIS OF THE CATEGORIES CLASS OF COMPOUND AND THERAPEUTIC TARGET	33
FIGURE 21:	CROSS-ANALYSIS OF THE CATEGORIES CLASS OF COMPOUND AND APPLICATION	34
FIGURE 22:	DISTRIBUTION OF THE 20 MAIN IPC CODES	35
TABLE 7:	DESCRIPTION OF THE 20 MAIN IPC CODES	36
TABLE 8:	EVOLUTION OF THE MAIN IPC CODES	36

FIGURE 23:	MAIN APPLICANTS FOR THE ENTIRE PERIOD (1983-2006).....	37
FIGURE 24:	BREAKDOWN OF THE MAIN PATENT PORTFOLIOS.....	38
FIGURE 25:	MAJOR COLLABORATIONS BY NUMBER OF JOINT FILINGS FOR THE ENTIRE PERIOD (1983-2006).....	40
FIGURE 26:	THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006).....	42
FIGURE 27:	APPLICATIONS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006) ..	43
FIGURE 28:	CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FOR THE ENTIRE PERIOD (1983-2006).....	44
FIGURE 29:	MAJOR APPLICANTS FROM 1983-1992	45
TABLE 9:	EVOLUTION OF FILINGS BY MAJOR APPLICANTS FROM 1983-1992	46
FIGURE 30:	THE MAJOR COLLABORATIONS BY NUMBER OF JOINT FILINGS FROM 1983 TO 1992	48
FIGURE 31:	THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FROM 1983-1992	50
FIGURE 32:	APPLICATIONS OF THE MAJOR PLAYERS FROM 1983-1992	51
FIGURE 33:	CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 1983-1992	52
FIGURE 34:	MAJOR APPLICANTS FROM 1993 - 2000.....	53
TABLE 10:	EVOLUTION OF FILINGS BY APPLICANT FROM 1993-2000.....	54
FIGURE 35:	THE MAJOR COLLABORATIONS AND THE NUMBER OF JOINT FILINGS FROM 1993-2000	56
FIGURE 36:	THERAPEUTIC TARGETS OF THE MAJOR PLAYERS FROM 1993-2000	58
FIGURE 37:	APPLICATIONS OF THE MAJOR PLAYERS FROM 1993-2000	59
FIGURE 38:	CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 1993-2000	60
FIGURE 39:	MAJOR APPLICANTS FROM 2001 - 2006.....	61
TABLE 11:	EVOLUTION OF FILINGS BY APPLICANT FROM 2001- 2006.....	62
FIGURE 40:	THE MAJOR COLLABORATIONS AND JOINT FILINGS (2001-2006).....	64
FIGURE 41:	THERAPEUTIC TARGETS FROM 2001-2006.....	66
FIGURE 42:	APPLICATIONS OF THE MAJOR PLAYERS FROM 2001-2006	67
FIGURE 43:	CLASSES OF COMPOUNDS OF THE MAJOR PLAYERS FROM 2001-2006	68
TABLE 12:	THE MAIN INVENTORS FOR THE ENTIRE PERIOD (1983-2006)	70
FIGURE 44:	EXPERTISE FACTOR FOR THE ENTIRE PERIOD.....	71
FIGURE 45:	MOBILITY OF INVENTORS	72
FIGURE 46:	RESEARCH TEAMS FOR THE ENTIRE PERIOD (1983-2006).....	73
FIGURE 47:	INDUSTRIAL/INSTITUTIONAL FILINGS OF THE MAIN INVENTORS AND/OR EXPERTS.....	74
FIGURE 48:	THERAPEUTIC TARGETS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS	74
FIGURE 49:	CLASSES OF COMPOUNDS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS	75
FIGURE 50:	APPLICATIONS PROTECTED BY THE MAIN INVENTORS AND/OR EXPERTS.....	75
TABLE 13:	LIST OF THE MAIN INVENTORS (1983-1992).....	79
FIGURE 51:	LIST OF EXPERTS (1983-1992).....	80
FIGURE 52:	THE MAJOR COLLABORATIONS AMONG INVENTORS (1983-1992).....	81

FIGURE 53:	THERAPEUTIC TARGETS OF THE MAIN INVENTORS (1983-1992)	82
FIGURE 54:	APPLICATIONS OF THE MAIN INVENTORS (1983-1992)	83
FIGURE 55:	CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (1983-1992)	84
TABLE 14:	LIST OF THE MAIN INVENTORS (1993-2000)	85
FIGURE 56:	LIST OF EXPERTS (1993-2000)	86
FIGURE 57:	THE MAJOR COLLABORATIONS AMONG INVENTORS (1993-2000)	88
FIGURE 58:	THERAPEUTIC TARGETS OF THE MAIN INVENTORS (1993-2000)	89
FIGURE 59:	APPLICATIONS OF THE MAIN INVENTORS (1993-2000)	90
FIGURE 60:	CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (1993-2000)	91
TABLE 15:	MAIN INVENTORS (2001-2006)	92
FIGURE 61:	LIST OF EXPERTS (2001-2006)	93
FIGURE 62:	THE MAJOR COLLABORATIONS AMONG INVENTORS (2001-2006)	95
FIGURE 63:	THERAPEUTIC TARGETS OF THE MAIN INVENTORS (2001-2006)	96
FIGURE 64:	APPLICATIONS OF THE MAIN INVENTORS (2001-2006)	97
FIGURE 65:	CLASSES OF COMPOUNDS OF THE MAIN INVENTORS (2001-2006)	98
TABLE 16:	LIST OF EMERGING INVENTORS	99
TABLE 17:	EVOLUTION OF FILLINGS BY EMERGING TOPICS	106
FIGURE 66:	EMERGING TOPICS BY APPLICANTS	106
FIGURE 67:	APPLICANTS FOR EMERGING TPPICS	107
FIGURE 68:	AUTHORS FOR EMERGING TOPICS	108

ORDER FORM

Complete, sign and send this order form by email ipoverview@fist.fr or by fax +33 (0) 1 40 51 78 58
or purchase your report directly on line <http://www.frinnov.fr>

Delivery Information

Title: Last Name: First Name:
Company:
Email: Phone:
Address:
.....
Zip: City: Country:

Overview

Billing address (if different)

.....
.....
.....

I hereby state that I have the authority to place orders for the above mentioned company (if applicable) and accept and understand Frinnov's Terms and Conditions of Sale accessible on line: <http://www.frinnov.fr>

Date: Signature:

Please take my order for the following report

Qty	Description	Price Ea.	Total
1	IP Overview "HIV"	1 625,00 €	1 625,00 €
		VAT (19.6%)	318,50 €
		Total	1 943,50 €

Payment method

- Cheque payable to FIST and sent to FIST SA, 83 Bd Exelmans, FR-75016 Paris
- Bank transfer: BNP Paribas, Paris AG-Centrale Entreprises, Bank code: 30004, Branch code: 00818, Account No: 00021375689 27

RIB : 30004 00818 00021375689 27
IBAN : FR76 3000 4008 1800 0213 7568 927
SWIFT / BIC : BNPAFRPPVD

For EU Member (outside France), kindly state your VAT number:



FRINNOV

www.frinnov.fr